Tag: 贵族宝贝VKO

Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger

first_img By Adam Feuerstein Aug. 26, 2019 Reprints Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Biotech Adam Feuerstein Amgen said Monday that it will buy the psoriasis pill Otezla from Celgene, which is selling the medicine to remove an antitrust obstacle from its planned merger with Bristol-Myers Squibb.The purchase price for Otezla is $13.4 billion — higher than many analysts expected. Celgene sells psoriasis pill to Amgen for $13.4 billion, clearing way for close of Bristol merger What is it? Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. [email protected] GET STARTEDcenter_img Log In | Learn More What’s included? Ric Francis/AP STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. About the Author Reprints Tags biotechnology Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTED @adamfeuerstein last_img read more

Read More